AI-generated analysis. Always verify with the original filing.
The provided document content for GT Biopharma, Inc.'s Q3 2025 10-Q/A filing does not contain the specific financial statements or XBRL data required to report on overall performance, revenue, profit drivers, or forward-looking significance. The document explicitly states that the company qualifies as a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk. The primary substantive disclosure relates to internal controls, where management concluded that disclosure controls and procedures were not effective as of September 30, 2025. A material weakness in internal control over financial reporting was identified related to the misclassification of Greenshoe Rights as equity instead of a liability under ASC 480, requiring a restatement of interim financial data for the quarterly periods ended June 30, 2025, and September 30, 2025. No changes in internal controls were reported for the most recent fiscal quarter. A remediation plan involving engaging an accounting consultant for complex transactions was adopted subsequent to September 30, 2025. No financial figures for revenue, profit, or cash flow are provided in the available text.